Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20862100 | 0.82 | ALDH1A1 (0.51) | HTTALDH1A1GAAKDM4ECYP2C9 | |
| SCHEMBL14344856 | 0.77 | HTT (0.56) | HTTALDH1A1GAAKDM4ELMNA | |
| SCHEMBL1520613 | 0.77 | HTT (0.89) | HTTALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30530619 | 0.77 | HTT (0.89) | HTTALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4965838 | 0.77 | KMT2A (0.47) | HTTALDH1A1GAALMNANPSR1 | |
| SCHEMBL4962542 | 0.77 | HPGD (0.50) | HTTALDH1A1GAAKDM4ELMNA | |
| SCHEMBL5948593 | 0.77 | NPC1 (0.49) | ALDH1A1GAALMNAMAPTHPGD | |
| SCHEMBL4963561 | 0.77 | KMT2A (0.51) | HTTALDH1A1GAALMNAMAPT | |
| SCHEMBL18544668 | 0.76 | LMNA (0.50) | ALDH1A1GAALMNAMAPTHPGD | |
| SCHEMBL10330512 | 0.76 | HTT (0.86) | HTTALDH1A1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606265-B1 | 2, 4- DI (PHENYLAMINO) PYRIMIDINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-02-02 | — | — | EP | disclosed |
| EP-2275413-A1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| WO-2008074858-A1 | INTERMEDIATES AND PROCESS FOR THE PRODUCTION OF 5-SUBSTITUTED TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007141253-A1 | PROCESS FOR THE PRODUCTION OF INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC IMIDAZOPYRIDINES | NYCOMED GMBH (DE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1696921-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005058325-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-5491233-A | Catalytic asymmetric reduction of trisubstituted olefins | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5489682-A | Catalytic asymmetric reduction of enamines | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-02-06 | — | — | US | disclosed |
| WO-1995002567-A1 | CATALYTIC ASYMMETRIC REDUCTION OF TRISUBSTITUTED OLEFINS AND ENAMINES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | HTT 1383/4885ALDH1A1 1722/4885GAA 37/4885 |
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | HTT 3326/4885ALDH1A1 76/4885GAA 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.